ET
AMRX icon

Entropy Technologies’s Amneal Pharmaceuticals AMRX Stock Holding History

Entropy Technologies’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-32,757
Closed -$259K – 709
2024
Q4 		$259K Buy
+32,757
New +$275K 0.03% 574

Other funds holding AMRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Entropy Technologies's AMRX Position: Q1 2025 in Review

Entropy Technologies sold out of Amneal Pharmaceuticals (AMRX) in Q1 2025, closing a stake of 32,757 shares — an estimated $259K sold.

Entropy Technologies first reported a position in AMRX in Q4 2024 and held it in 1 quarter. The position peaked at $259K in Q4 2024. 237 funds tracked by Wall St. Rank hold AMRX as of Q1 2025.

  • Entropy Technologies reported no remaining Amneal Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Entropy Technologies sold 32,757 Amneal Pharmaceuticals shares in Q1 2025, an estimated $259K.
  • Entropy Technologies first reported a position in Amneal Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Entropy Technologies's Amneal Pharmaceuticals position peaked at $259K in Q4 2024.
  • 237 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2025.

Based on Entropy Technologies's 13F filing for Q1 2025, filed 12 May 2025.